Mark Prvulovic

Mark Prvulovic


Before joining The Motley Fool, Mark worked as a freelance financial writer covering a variety of markets. Now he spends most of his time researching promising biotech and cannabis stocks, but from time to time will write about whatever catches his interest no matter the industry.

Recent articles

Is CRISPR Therapeutics a Buy?

With its head start in the emerging gene-editing market, does CRISPR deserve investors' money more than its rivals do?